Overall Status

Active, not recruiting (1)

Completed (1)

Terminated (1)

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Celldex Therapeutics (1)

M.D. Anderson Cancer Center (1)

Molecular Templates, Inc. (1)

Collaborator

Merck Sharp & Dohme LLC (1)

Pharmacyclics LLC. (1)

Intervention

cdx-1140 (1)

cdx-301 (1)

chemotherapy (1)

ibrutinib (1)

mt-3724 phase 1 (1)

mt-3724 phase 2 (1)

pembrolizumab (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

Small Lymphocytic Leukemia

Showing NaN - NaN of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in

Active, not recruiting

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
+2 more

Ibrutinib

Houston, Texas

University of Texas MD Anderson Cancer Center

Jan 20, 2023

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed

Melanoma
+25 more

CDX-1140
+3 more

Scottsdale, Arizona
+10 more

Sep 27, 2022

Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724

Terminated

Has Results

Non-Hodgkin's B-cell Lymphoma
+5 more

MT-3724 Phase 1
MT-3724 Phase 2

Tucson, Arizona
+40 more

Jul 18, 2022